NASA's red planet rover shares a cool close-up of Mars mud
While it's already shared strong evidence that the red planet once had the right conditions for such a scenario, Curiosity continues to learn more about Mars through science expeditions that include drilling for rock samples that it then analyzes in its onboard laboratory.
Recommended Videos
On Thursday, the hardy rover shared a striking image (top and below) showing its latest drilling site, with the disturbed Mars mudstone appearing so close to the lens that you feel like you can almost reach out and touch it. Take a closer look and marvel at the astonishing detail present in the image, and then consider that it exists not on Earth but in a place currently some 180 million miles from where you're sat now.
Meet 'Altadena,' my 43rd drill hole.
It's named after a city near where I was built back on Earth. I've got more sampling to do as a I scale Mount Sharp, unraveling its history one rocky layer at a time. pic.twitter.com/qyKyeLCZjO — Curiosity Rover (@MarsCuriosity) June 12, 2025
'Meet 'Altadena,' my 43rd drill hole,' Curiosity said in its post. 'It's named after a city near where I was built back on Earth. I've got more sampling to do as a I scale Mount Sharp, unraveling its history one rocky layer at a time.'
The mudstone on Mars is a type of sedimentary rock formed from very fine particles of silt and clay that settled in ancient water bodies. It's essentially the remnants of ancient lakebeds, suggesting that Mars held liquid water for an extensive period a long time ago.
Curiosity is conducting its work on Mount Sharp, which it's been exploring for much of its time on Mars. The feature is an 18,000-foot-high mountain in the middle of Gale Crater, and whose sedimentary layers, formed over billions of years, hold clues to Mars' watery past and potential habitability.
Curiosity's mission was originally supposed to last no more than two years but was extended indefinitely after it successfully met its initial goals. In 2021, NASA landed the even more powerful Perseverance rover on Mars in a mission that complements the Curiosity rover by advancing the search for signs of ancient microbial life on the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Could Comet 3I/Atlas Be A Threat? Here's What Experts Are Saying
On the 1st of July 2025, the Asteroid Terrestrial-Impact Last Alert System (ATLAS) in Chile spotted a new comet entering our solar system. This comet was named 3I/ATLAS, as it's only the third interstellar object humans observed passing through our solar system. The previous two interstellar bodies discovered were 1I/'Oumuamua (spotted in 2017), and 2I/BORISOV (detected in 2019). It seems that 3I/ATLAS is similar to 2I/BORISOV by its icy composition. Beyond that, we don't know much about the new interstellar visitor. Scientists rush to observe 3I/ATLAS and discover as much as they can, as it's predicted by its current trajectory and speed to leave our solar system by the end of the year. It will come closest to our sun in late October 2025, and the sun will melt some of its ice, which means 3I/ATLAS might get a robust comet tail composed of vapor and dust. Currently, this comet has a faint coma, the cloud of dust and gas that surrounds its nucleus. But this might change with its approach to the sun. Another interesting fact is that 3I/ATLAS will pass through Mars' orbit, and we don't know what will happen then. The fact that it was ATLAS that first discovered this comet got some people concerned. The Asteroid Terrestrial-Impact Last Alert System has a defensive nature. It's designed to spot and warn us about comets, asteroids, or other space objects that might be on a collision course with Earth. However, according to NASA, the interstellar object will most likely fly far enough from our planet without posing any danger. Read more: This Is How Most Life On Earth Will End What NASA Has To Say The ATLAS observatory in Chile is part of NASA's early warning program, spotting and defining all near-Earth objects (NEOs), especially if they're asteroids and comets that could strike our planet. ATLAS uses a network of wide-field telescopes that scan the night sky above Earth 24/7. Although designed for planetary defense against hazardous space objects, ATLAS is capable of detecting non-threatening, but scientifically interesting objects as well. The telescopes that are part of this defensive network are based in several observatories around the globe (South Africa, California, and Chile, to name a few), providing the researchers with round-the-globe coverage of the night sky. Of course, when 3I/ATLAS was first discovered, the first things determined were its trajectory and velocity. It was concluded that this comet is traveling at the speed of 137,000 miles/hour (61km/s), and the closest it will approach Earth is at 1.8 astronomical units (170 million miles, or 270 million kilometers, from Earth). NASA has ultimately concluded that 3I/ATLAS poses no threat to our planet. That said, the most interesting known fact about this interstellar visitor is its age. Following its current trajectory, scientists were able to determine 3I/ATLAS originated in a part of the Milky Way that we know is older than our solar system; meaning it's potentially older than 4.6 billion years old. It's estimated that 3I/ATLAS is around 7 billion years old, making it the oldest comet observed by humans so far. Could It Be An Alien Probe? Although very little is known about 3I/ATLAS so far, there are many interesting theories surrounding this interstellar visitor. Harvard-based astrophysicist Abraham Loeb and colleagues from the UK's Initiative for Interstellar Studies, Adam Hibbert and Adam Crowl, believe this interstellar object is not a comet at all; but an alien probe coming from afar to scan Earth and its surroundings. This is not the first time Loeb has suggested such a thing. In 2017, when Oumuamua was discovered, he claimed it was an alien probe due to its unusual shape, acceleration, reflectivity, and lack of trailing gases. Although he didn't come out with any specifics about 3I/ATLAS, Loeb warns that any interstellar object should be observed as possible alien technology. As of now, there's no evidence that 3I/ATLAS is anything but an interstellar comet passing through our solar system. It was lucky that ATLAS detected it, as it is believed millions of such objects pass near or through our system without ever being detected. Scientists such as Loeb might not be completely wrong, however. 3I/ATLAS is a unique interstellar comet, and we should pay more attention to it. Read the original article on BGR. Solve the daily Crossword
Yahoo
6 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool
Yahoo
6 hours ago
- Yahoo
Kumail Nanjiani recalls meeting Elon Musk while shooting 'Silicon Valley':' ''He didn't like the show'
Kumail Nanjiani said that Elon Musk was "upset" with the opening scene of Silicon Valley. Nanjiani appeared on an episode of Mike Birbiglia's podcast Working It Out, where he recalled some of the experiences he had with tech giants while on the show. "He didn't like the show," Nanjiani said of Musk. The Eternals actor remembered meeting the Tesla CEO, who said the parties he attended were "much cooler" than those depicted on Silicon Valley. The premiere opens with Kid Rock playing at a tech event to a sparse, dead crowd. "It was like, 'Yeah, man. You're one of the richest people in the world. We're, like, losers on the show. Of course your parties are better than my parties. What are you talking about?'" the Big Sick star said. The comedian also met Mark Zuckerberg while doing the show, but made a bad impression. He and his costar Martin Starr had presented at the Breakthrough Awards, which were co-founded by Zuckerberg, in 2016. During the ceremony, the Silicon Valley actors called back to a joke from the season 1 finale about giving hand jobs to an entire conference room of people. They retooled that bit to accommodate the number of scientists at the Breakthrough Awards and bombed. Nanjiani said he doesn't blame the Facebook founder for disliking him after that moment. "He was like, 'What the f--- was that?'" Nanjiani said. "And truly in that moment he was right." Check out the full episode of Working It Out with Kumail Nanjiani below. Read the original article on Entertainment Weekly
